FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to experimental pharmacology and genetic technologies. Described method is as follows. In dysferlin-deficient mice B6.A/J-Dysfprmd there is a marked increase in the duration of swimming with a load after a single introduction of a preparation based on adeno-associated virus of serotype 9 in dose of 1*1012 units of virus with the DYSF gene in amount of 50 mcl in the following muscles of both hind limbs: m. vastus lateralis, m. tibialis anterior, m. gastrocnemius lateralis (per animal in total 300 mcl) in test "Forced swimming with load" in 3 months after introduction of AAV9-DYSF-DV.
EFFECT: invention can be used to improve physical performance.
1 cl, 1 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INCREASING PHYSICAL ENDURANCE IN EXPERIMENT ON DYSFERLIN-DEFICIENT MICE | 2023 |
|
RU2833672C1 |
| METHOD OF MAINTAINING STATIC ENDURANCE IN DYSFERLIN-DEFICIENT MICE IN EXPERIMENT | 2023 |
|
RU2829651C1 |
| METHOD OF MYODYSTROPHY CORRECTION USING ADENO-ASSOCIATED VIRAL VECTOR IN EXPERIMENT | 2022 |
|
RU2821544C1 |
| METHOD FOR CORRECTING MUSCULAR DYSTROPHY USING PLASMID DNA IN DYSFERLIN-DEFICIENT MICE | 2022 |
|
RU2805357C1 |
| SET OF RECOMBINANT GENETIC VECTORS CODING BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV-1, IMMUNOBIOLOGICAL PREPARATION FOR TREATMENT AND PREVENTION OF HIV INFECTION AND METHOD OF ITS APPLICATION | 2024 |
|
RU2833072C1 |
| USING VECTOR FOR REDUCING IMMUNE RESPONSE IN VIRAL DELIVERY OF AIPL1 | 2023 |
|
RU2818342C1 |
| PREPARATION FOR STIMULATING REGENERATION AND NEUROPROTECTION OF NERVE TISSUE AND METHOD OF USING SAME | 2023 |
|
RU2828544C1 |
| NUCLEIC ACID DESIGNED TO REDUCE MAMMALIAN BODY WEIGHT, EXPRESSION VECTOR FOR EXPRESSION IN MAMMALIAN CELLS, METHOD FOR ITS DELIVERY AND METHOD FOR REDUCING MAMMALIAN BODY WEIGHT | 2023 |
|
RU2810191C1 |
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
| ADENO-ASSOCIATED VIRUS VECTOR FOR THERAPEUTIC DELIVERY INTO THE CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2751952C2 |
